Mind Medicine's MM120 program for generalized anxiety disorder receives FDA breakthrough therapy designation, boosting stock value.

Mind Medicine (MNMD) stock increased on Thursday after the company received FDA breakthrough therapy designation for its MM120 program in treating generalized anxiety disorder (GAD). MM120's Phase 2b study demonstrated positive 12-week durability data. This breakthrough designation could speed up the development and advancement of MM120's treatment for GAD.